Investor Alert

New York Markets Open in:

Market Pulse Archives

Dec. 16, 2010, 12:04 p.m. EST

U.S. FDA to rescind Avastin for breast cancer

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Roche Holding AG ADR (RHHBY)
  • X
    Roche Holding AG (ROG)

or Cancel Already have a watchlist? Log In

By Sue Chang

SAN FRANCISCO (MarketWatch) -- The U.S. Food and Drug Administration will recommend the removal of Roche's /zigman2/quotes/208994986/delayed RHHBY +1.39% /zigman2/quotes/206324342/delayed CH:ROG +0.96% Avastin for treatment of breast cancer as the drug has not been shown to be safe and effective, the FDA said in a statement Thursday. "The agency is making this recommendation after reviewing the results of four clinical studies of Avastin in women with breast cancer and determining that the data indicate that the drug does not prolong overall survival in breast cancer patients or provide a sufficient benefit in slowing disease progression to outweigh the significant risk to patients," said the FDA. But the drug itself will not be removed from the market and the decision will not have any impact on its use for colon, kidney, brain, and lung cancers.

US : U.S.: OTC
$ 48.92
+0.67 +1.39%
Volume: 473,499
Oct. 15, 2021 4:00p
P/E Ratio
Dividend Yield
Market Cap
$339.64 billion
Rev. per Employee
CH : Switzerland: SWX
CHF 363.70
+3.45 +0.96%
Volume: 214,035
Oct. 18, 2021 11:37a
P/E Ratio
Dividend Yield
Market Cap
CHF313.47 billion
Rev. per Employee

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.